News
Data from the FIBRONEER-IPF and FIBRONEER-ILD studies, published in The New England Journal of Medicine, highlight ...
Roche’s Susvimo Lands FDA Approval for Diabetic Retinopathy Based on Phase III Pavilion Trial Data
One-year results from the Pavilion study showed patients who received Susvimo (ranibizumab) refilled every nine months ...
In this video interview, Michel van Harten, MD, CEO, myTomorrows, highlights how artificial intelligence can be used to address logistical barriers such as access and treatment cost.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback